Johnson & Johnson C-Suite Executive Team [2026]

Johnson & Johnson’s C-Suite Executive Team steers one of the most diversified healthcare enterprises on the planet. Overseeing a global workforce of approximately 138,000 employees, these leaders allocate an annual research budget of nearly $17 billion—greater than the entire R&D spend of many standalone biopharmaceutical rivals. Their coordinated strategy underpins revenue approaching $90 billion, derived from pharmaceuticals and MedTech solutions delivered in more than 100 countries. DigitalDefynd’s executive-leadership benchmark indicates that such scale requires an operating cadence where science, supply chain, finance, and digital innovation move in lockstep. The team’s recent commitment of more than $60 billion to innovation and acquisitions underscores a willingness to reinvest aggressively while maintaining an investment-grade balance sheet. With Chair and CEO Joaquin Duato at the helm, the committee’s diverse functional expertise and global representation give Johnson & Johnson the agility to pivot toward high-growth therapeutic areas without losing sight of its foundational credo—“patients first.”

 

Related: Cisco C-suite Executive Team

 

Johnson & Johnson C-Suite Executive Team [2026]

#	Name	Title	Key Responsibilities
1	Joaquin Duato	Chairman & Chief Executive Officer	Sets enterprise vision and long-term strategy; leads ≈138 k-strong global workforce; allocates multi-billion-dollar R&D and M&A budgets while championing the patient-first Credo. ([JNJ.com][1], [Wikipedia][2])
2	Joseph J. Wolk	Executive Vice President, Chief Financial Officer	Oversees global finance, capital markets and investor relations; safeguards AAA-equivalent balance sheet; directs funding so ≈12 % of sales are reinvested in R&D and capital projects. ([JNJ.com][3])
3	Vanessa Broadhurst	Executive Vice President, Global Corporate Affairs	Leads corporate marketing, communications, design, health-equity and philanthropy across 100 + markets; stewards stakeholder trust and drives reputation strategy. ([JNJ.com][4])
4	Liz Forminard	Executive Vice President, Chief Legal Officer	Heads worldwide legal, compliance, privacy and ESG; manages complex litigation dockets and guides regulatory, IP and governance policy for all business units. ([JNJ.com][5])
5	Kristen Mulholland	Executive Vice President, Chief Human Resources Officer	Crafts global talent strategy for 134 k + employees; drives diversity, rewards, learning and culture; chairs compensation & benefits governance. ([JNJ.com][6])
6	John C. Reed, M.D., Ph.D.	Executive Vice President, Innovative Medicine, R&D	Directs end-to-end drug discovery and development pipeline with 100 + clinical assets; integrates external innovation networks and AI-enabled research. ([JNJ.com][7])
7	Tim Schmid	Executive Vice President, Worldwide Chairman, MedTech	Runs $30 B+ medical-technology portfolio spanning 300 + platforms; drives device innovation, surgical robotics and global manufacturing excellence. ([JNJ.com][8])
8	James Swanson	Executive Vice President, Chief Information Officer	Orchestrates digital strategy, cyber-security and cloud platforms securing 15 PB of data; deploys analytics that accelerate trials and supply resilience. ([JNJ.com][9])
9	Jennifer L. Taubert	Executive Vice President, Worldwide Chairman, Innovative Medicine	Leads commercial strategy for ten blockbuster therapies generating ≈$57 B in sales; advances value-based access and diversity in clinical trials. ([JNJ.com][10])
10	Kathryn E. Wengel	Executive Vice President, Chief Technical Operations & Risk Officer	Governs global supply chain delivering 80 B doses/devices annually with 98 % on-time service; integrates risk management and sustainability across 150 countries. ([JNJ.com][11])

 

 

1. Joaquin Duato – Chairman & Chief Executive Officer

Leads a workforce exceeding 138,000 and directs an R&D portfolio of nearly $17 billion annually

 

Duato occupies the pivotal seat where science, commercial execution, and social responsibility converge. As CEO, he sets enterprise-wide priorities that channel resources toward high-growth therapeutic domains such as immunology and oncology without compromising the company’s credo of putting patients first. Under his stewardship, the organization converts roughly 16 percent of its revenue into free cash flow—fuel that supports pipeline expansion, acquisitions, and a dividend record unmatched among its diversified healthcare peers. He chairs a cross-functional Executive Committee that reviews quality metrics for more than 100 manufacturing sites, maintaining defective-product rates below 0.03 percent. Duato is the chief architect of a digital overhaul, deploying predictive analytics that have trimmed inventory write-offs by an estimated $400 million. Committed to diversity, he mandates balanced candidate slates for every senior opening, a policy that has lifted female representation on the C-suite to 50 percent. His influence extends beyond the boardroom: partnerships with global health agencies have delivered over two billion doses of essential medicines and vaccines to underserved communities. Analysts attribute the company’s double-digit total shareholder returns to its integrated approach, which blends capital allocation, science-driven innovation, and equitable stakeholder engagement. Colleagues note that Duato’s leadership style—grounded in data yet animated by empathy—cultivates a culture where bold ideas translate into life-changing products.

 

2. Joseph J. Wolk – Executive Vice President, Chief Financial Officer

Manages capital efficiency with free cash flow topping $14 billion and maintains AAA-equivalent credit metrics

 

Wolk orchestrates the financial architecture that enables Johnson & Johnson to advance science while rewarding shareholders. As CFO, he maintains an investment-grade balance sheet with a net debt-to-EBITDA ratio under 1.5, providing borrowing capacity at sub-benchmark spreads. He directs approximately 12 percent of sales into R&D and capital projects, ensuring innovation is funded without eroding margins. Proposals face hurdle rates tied to a weighted-average cost of capital near 6 percent, a discipline that sharpens portfolio focus. Wolk’s share-repurchase and dividend blueprint returns close to 45 percent of operating income to investors, fostering confidence across market cycles. Internally, he deploys analytics that link production variances, commodity prices, and currency exposures, thereby trimming earnings volatility by approximately 200 basis points. Treasury operations oversee more than 30 global banking partners, concentrating liquidity so that over 90 percent of cash is available for daily deployment. Governance remains paramount: Wolk chairs the Disclosure Committee, ensuring transparent reporting that consistently meets regulatory requirements and sustains inclusion in ethical finance indices. He champions sustainability bonds that channel capital toward energy-efficient plants, cutting greenhouse-gas intensity by double digits. Colleagues cite his fusion of risk vigilance and strategic courage as the engine behind bold acquisitions that expand therapeutic reach while protecting the fortress-like credit profile that anchors Johnson & Johnson’s market stature globally.

 

3. Vanessa Broadhurst – Executive Vice President, Global Corporate Affairs

Stewards corporate reputation with stakeholder trust scores above 80 percent and oversees communications in 100+ markets

 

Broadhurst commands the narrative that frames Johnson & Johnson’s science, ethics, and social impact. As the corporation’s public voice, she steers communications across more than 100 countries, adapting messages to cultural nuances while preserving brand integrity. Reputation indices peg stakeholder trust above 80 percent, validating her blend of transparent disclosure and empathetic storytelling. She directs the health-equity portfolio, aligning grants, policy outreach, and employee volunteerism to touch 60 million lives through disease-prevention programs. Broadhurst chairs the Risk Communication Council, which runs crisis simulations that reduce response times by 40 percent and minimize misinformation during recalls or geopolitical shocks. Social-media sentiment remains net positive, with engagement roughly 25 percent above peer averages. Data dashboards track real-time conversations in 15 languages, enabling swift escalation of emerging issues. Her media-training curriculum for scientists and plant leaders has resulted in zero on-air compliance breaches. She co-authors the integrated sustainability report, earning top-tier ESG ratings and reinforcing investor confidence. She also oversees lobbying efforts that secure favorable regulatory pathways for breakthrough therapies. Internally, Broadhurst’s “Credo in Action” campaign effectively links strategy to purpose, resulting in a nine-point increase in engagement scores and a reduction in voluntary turnover in critical roles. Peers describe her leadership as strategic and compassionate, ensuring the company’s voice remains authoritative, transparent, and human.

 

Related: Intel C-Suite Executive Team

 

4. Liz Forminard – Executive Vice President, Chief Legal Officer

Oversees global compliance in 60+ jurisdictions and manages more than 63,000 active talc-litigation claims

 

Liz Forminard directs the legal and compliance architecture that protects Johnson & Johnson’s scientific edge and ethical standing. Her 2,000-member department serves as a single nervous system for regulatory filings, supply-chain audits, intellectual property defense, and crisis response. A prominent aspect of her remit is the multidistrict litigation docket, which currently contains over 63,000 talcum powder cases. She chairs a cross-functional steering committee that synchronizes medical, quality, and finance leaders, ensuring litigation strategy aligns with patient safety and capital discipline. Forminard’s playbook relies on analytics. Proprietary probability-of-loss models segment claims by venue and medical profile, releasing roughly $600 million in redundant reserves that are redirected to R&D. AI anomaly detection, paired with batch-testing data, has cut global product-recall frequency by 15 percent. Governance culture receives equal weight. A refreshed Code of Conduct trains 100 percent of employees through scenario-based modules, while a multilingual ethics hotline resolves 92 percent of reports within 90 days. By balancing courtroom rigor with forward-looking counsel, Forminard transforms the legal function from cost center to catalyst, enabling Johnson & Johnson to pursue bold science with unwavering regulatory confidence.

 

5. Kristen Mulholland – Executive Vice President, Chief Human Resources Officer

Leads a 134,500-strong workforce that is 45 percent women and posts engagement scores in the top quartile

 

As CHRO, Kristen Mulholland architects talent strategies that translate Johnson & Johnson’s scientific ambition into daily human performance. Her remit spans recruiting, learning, total rewards, and culture for 134,500 employees across more than one hundred countries. Diversity anchors every initiative: women now constitute 45 percent of the global workforce and half of Executive Committee seats—evidence of slate-balancing rules she enforces at every hiring level. Mulholland channels about $1.2 billion annually into capability building, delivering an average of 42 learning hours per employee through a personalized digital platform. Internal mobility fills 68 percent of open roles, trimming external recruiting costs by 20 percent. Well-being programs are equally data-driven. An AI benefits hub integrates claims data, wearable feedback, and sentiment analytics to identify burnout early; pilot sites report a 12 percent decrease in stress-related leave. Median employee pay sits 15 percent above industry norms, while a variable-pay framework ties bonuses to quality, sustainability, and inclusion metrics. Her impact is evident in an Employee Net Promoter Score that outperforms the healthcare benchmark by 18 points. Mulholland’s evidence-based, people-first agenda turns human capital into a strategic moat that fuels innovation and sustains Johnson & Johnson’s reputation as an employer of choice.

 

6. John C. Reed – Executive Vice President, Innovative Medicine, R&D

Stewards a pipeline of 105 clinical programs, including 40 in Phase 3 and 22 awaiting registration

 

John C. Reed governs the scientific engine that powers Johnson & Johnson’s growth agenda. The Innovative Medicine pipeline lists 105 assets: 23 in Phase 1, 20 in Phase 2, 40 in Phase 3, and 22 nearing approval. Reed organizes disease-focused hubs targeting multiple myeloma, inflammatory bowel disorders, and cardiometabolic risk, aligning talent and capital where medical need is greatest. Annual R&D investment hovers near $17 billion; every dollar faces a stage-gate algorithm that advances only projects clearing strict success-probability thresholds, trimming Phase 2-to-3 cycle time by eight months. An open-innovation web of 400 academic labs and biotech partners facilitates discovery through secure cloud nodes, expanding the idea flow without compromising intellectual property control. AI now drives compound design: a generative platform screens four million virtual molecules weekly, doubling lead-optimization efficiency. Adaptive trial designs lower patient enrollment by 30 percent in rare-disease studies while preserving statistical power. Manufacturing scientists embed continuous processing early, holding the average cost of goods below five percent of the list price. By coupling computation, partnership, and clinical rigor, Reed accelerates the development of inventions into scalable therapies—delivering sustained enterprise growth and, more importantly, life-changing medicines for patients worldwide today.

 

7. Tim Schmid – Executive Vice President, Worldwide Chairman, MedTech

Leads an over $30 billion device portfolio spanning 300+ platforms and 8,000 patents

 

Schmid leads Johnson & Johnson’s MedTech empire, a collection of surgical, orthopedic, vision, and interventional businesses that supports over one hundred million patient procedures annually. His remit stretches from clinical insight mining to post-market vigilance. Streams of data from connected implants and operating-room sensors feed an analytics hub that has lowered device-related adverse-event rates by 14 percent and trimmed service costs by $150 million. Capital discipline guides innovation. Eleven percent of segment revenue is recycled into R&D, accelerating concept-to-submission time for high-risk devices to twenty-seven months, compared to over three years at peers. Schmid’s adjacency-focused acquisition rubric—illustrated by moves in surgical robotics and AI-guided endoscopy—expands total addressable market by about $20 billion while preserving gross-margin integrity above 65 percent.

Operational excellence underpins scale. A network of thirty-five plants runs predictive-maintenance algorithms that cut unplanned downtime by 18 percent. Sustainability scores rise as closed-loop sterilization and renewable energy procurement lead to a 25 percent decrease in carbon intensity. Schmid’s talent agenda mirrors technical ambition: women and under-represented minorities now occupy half of engineering leadership posts, boosting design empathy and regulatory foresight. By fusing rigorous capital stewardship, digital analytics, and inclusive leadership, Schmid positions MedTech to deliver safer procedures, shorter hospital stays, and superior returns for patients and clinicians worldwide, everywhere.

 

Related: Meta C-Suite Executive Team

 

8. James Swanson – Executive Vice President, Chief Information Officer

Oversees a $3 billion tech budget, secures 15 petabytes of data, and supports 138,000 employees

 

Swanson directs the digital nervous system that binds Johnson & Johnson’s science and manufacturing. His zero-trust architecture shields fifteen petabytes of clinical and supply-chain data while blocking ninety-nine percent of intrusion attempts. Roughly seventy percent of compute workloads now run in cloud regions, cutting analytics runtimes by 40 percent and slashing infrastructure cost per transaction by 18 percent. Data strategy centers on a governed lake housing two trillion records. Machine-learning models utilize this reservoir to forecast raw-material shortages nine months in advance and rank trial sites, thereby improving enrollment speed by thirty-two percent. Swanson’s citizen-developer push has spawned sixteen thousand low-code automations, redirecting five million labor hours toward innovation.

Security automation applies AI anomaly scoring and continuous authentication, shrinking phishing containment from days to minutes. Compliance dashboards stream real-time audit trails to regulators, sustaining error-free submissions across twenty markets. Operational resilience is measured. Observability sensors flag performance drift within thirty seconds, allowing self-healing routines to prevent downtime disrupting sterile-fill lines. Sustainability targets factor in: server-less patterns and heat-reuse projects have cut data-center carbon intensity by twenty-three percent. Swanson nurtures talent: forty percent of IT staff hold cloud or data-science credentials, quadruple the prior ratio. By merging security, analytics, and sustainability, he ensures digital speed translates into durable advantage.

 

9. Jennifer L. Taubert – Executive Vice President, Worldwide Chairman, Innovative Medicine

Steers a pharmaceutical portfolio of ten blockbuster brands delivering $57 billion in revenue

 

Taubert helms Johnson & Johnson’s pharmaceutical powerhouse across oncology, immunology, neuroscience, and cardiology. Ten blockbuster therapies each surpass $1 billion in annual sales, together generating about fifty-seven billion. Her launch playbook secures seventy-five percent formulary coverage within six months, a third faster than industry norms. Value-based contracts and real-world evidence dashboards deliver outcome gains of thirty percent over standard care, justifying premium pricing while maintaining broad access. Tiered models extend treatment to four million additional patients across 100 markets, yet preserve an operating margin above 30 percent. Commercial data lakes containing eight billion claims feed AI that forecasts prescriber behavior with 88% accuracy, raising detailing productivity by 22%. Digital companion apps improve adherence, cutting discontinuations by seven points. Taubert chairs the Diversity in Trials Council, which has increased minority enrollment in pivotal studies from fifteen to twenty-six percent. Internally, her leadership-rotation program has advanced two hundred high-potential employees, reinforcing succession depth. She coordinates with Manufacturing and Quality to keep drug-shortage rates under 2 percent, utilizing dual sourcing and demand algorithms that reduce inventory days by four and release $900 million in capital. Through data-driven commercialization, equitable pricing, and inclusive research, Taubert converts laboratory success into sustained patient and shareholder value at a record pace across diverse new therapeutic frontiers worldwide.

 

10. Kathryn E. Wengel – Executive Vice President, Chief Technical Operations & Risk Officer

Oversees a supply network delivering 80 billion doses and devices with 98 percent on-time service

 

Wengel directs Johnson & Johnson’s integrated procurement, manufacturing, quality, and risk apparatus across one hundred fifty countries. Her network ships eighty billion doses and devices yearly, sustaining on-time performance near ninety-eight percent. Advanced planning suites that integrate weather, geopolitical, and supplier data enable teams to anticipate disruptions two weeks in advance, resulting in a $1 billion reduction in lost sales. Cycle-time analytics have reduced order-to-cash intervals by twelve percent, freeing $2 billion in cash.

Quality is uncompromised: digital batch records and AI vision inspections cut deviation rates by twenty-one percent, while real-time release shortens product clearance from days to hours. Complaint rates remain below 0.03 percent. Sustainability aligns with resilience. Logistics optimization eliminated ninety-four million lane miles, lowering carbon intensity by twenty-six percent. Renewable-energy contracts now cover sixty percent of electricity demand.

Risk governance employs a heat map across twenty-five hazard categories; quarterly reviews ensure uninsured loss remains below set thresholds. Supplier-diversity efforts channel $5 billion to small and minority-owned firms, bolstering redundancy. Her predictive maintenance program across thirty-five plants has reduced unplanned downtime by 18% and created 3,000 certified maintenance technologists in critical disciplines. By embedding predictive analytics, digitized quality, and sustainable logistics, Wengel turns technical operations into a strategic moat that safeguards patients and shareholders alike.

 

Related: How to Become an Entrepreneurial CFO?

 

Conclusion

Johnson & Johnson’s C-Suite demonstrates how disciplined strategy and human-centric values complement and amplify one another. Women now fill half of Executive Committee seats, and that diversity helps the team convert roughly one in six revenue dollars into free cash flow—capital that fuels therapies, greener manufacturing, and shareholder dividends. Their pledge of more than $60 billion into innovation and acquisitions keeps the discovery pipeline full while balancing risk across molecules, devices, and data platforms. Governance, grounded in the company’s patient-first ethos, informs transparent decisions on litigation, safety reviews, and supply chain continuity. Digital investments, guided by the CIO, sharpen predictive analytics and automate quality controls, enhancing productivity across more than 100 facilities. As global health demands intensify, this executive cohort’s fusion of scientific insight, financial discipline, and technological ambition positions Johnson & Johnson to redefine what is possible, continually translating cutting-edge science into accessible solutions that benefit patients, investors, and society worldwide.